Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
Background: Data on vedolizumab (VDZ) use in inflammatory bowel disease (IBD) patients are still limited. We aimed to assess the effectiveness and tolerability of VDZ in a real-life clinical scenario. Methods: We retrospectively collected data of all consecutive IBD patients who started VDZ from Sep...
Main Authors: | Fabiana Zingone, Brigida Barberio, Federico Compostella, Giulia Girardin, Renata D’Incà, Carla Marinelli, Ilaria Marsilio, Greta Lorenzon, Edoardo Vincenzo Savarino |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756284820936536 |
Similar Items
-
The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
by: Neal Shahidi, et al.
Published: (2016-05-01) -
Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
by: Gilroy L, et al.
Published: (2014-05-01) -
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01) -
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01) -
A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
by: Ilaria Marsilio, et al.
Published: (2020-04-01)